Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Krystexxa Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Krystexxa (pegloticase) Coverage for Chronic Gout

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    HMSA coverage and prior authorization for Krystexxa in adults with chronic gout refractory to conventional therapy, including required clinical, documentation, and methotrexate-related criteria.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyKrystexxa (pegloticase) Coverage for Chronic Gout
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJune 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit the required precertification request using the HMSA medical specialty drug policy fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval period
    3 monthsConventional therapy trial
    < 6 mg/dL

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Serum uric acid response
    18 yearsMinimum age
    2/yearMinimum flare frequency